Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

Paola Queirolo, Francesco Spagnolo, Virginia Picasso, Laura Spano, Enrica Tanda, Valeria Fontana, Laura Giorello, Domenico Franco Merlo, Ester Simeone, Antonio Maria Grimaldi, Marcello Curvietto, Michele Del Vecchio, Paolo Bruzzi, Paolo Antonio Ascierto

Research output: Contribution to journalArticle

Abstract

BACKGROUND: BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression on prior single-agent BRAF inhibitor.

PATIENTS AND METHODS: In this two-centres, single-arm Phase 2 trial, we enrolled patients with systemic progressive disease during single-agent vemurafenib treatment. Participants received vemurafenib 960 mg twice daily or dose administered at time of disease progression with vemurafenib previous treatment and fotemustine 100 mg/m2 intravenously every three weeks. The primary endpoint was PFS.

RESULTS: Thirty-one patients were enrolled in the study; 16 patients had brain metastases at baseline. Median PFS was 3.9 months and 19 patients (61.3%) achieved disease control (1 CR, 4 PR, 14 SD). For patients achieving disease control, median duration of treatment was 6 months. Median OS was 5.8 months from enrolment and 15.4 months from start of previous vemurafenib. Five patients (16.1%) had a G3-4 AE, the most common being thrombocytopenia, which occurred in 3 patients.This trial is registered with ClinicalTrials.gov number NCT01983124.

CONCLUSION: The combination of vemurafenib plus fotemustine has clinical activity and an acceptable safety profile in BRAF-refractory patients.

Original languageEnglish
JournalOncotarget
DOIs
Publication statusE-pub ahead of print - Jul 13 2016

Fingerprint

fotemustine
Melanoma
PLX4032
Therapeutics
Survival

Keywords

  • Journal Article

Cite this

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib. / Queirolo, Paola; Spagnolo, Francesco; Picasso, Virginia; Spano, Laura; Tanda, Enrica; Fontana, Valeria; Giorello, Laura; Merlo, Domenico Franco; Simeone, Ester; Grimaldi, Antonio Maria; Curvietto, Marcello; Del Vecchio, Michele; Bruzzi, Paolo; Ascierto, Paolo Antonio.

In: Oncotarget, 13.07.2016.

Research output: Contribution to journalArticle

Queirolo, Paola ; Spagnolo, Francesco ; Picasso, Virginia ; Spano, Laura ; Tanda, Enrica ; Fontana, Valeria ; Giorello, Laura ; Merlo, Domenico Franco ; Simeone, Ester ; Grimaldi, Antonio Maria ; Curvietto, Marcello ; Del Vecchio, Michele ; Bruzzi, Paolo ; Ascierto, Paolo Antonio. / Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib. In: Oncotarget. 2016.
@article{493db5c0a6e246baba8f97a0f7b63c03,
title = "Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib",
abstract = "BACKGROUND: BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression on prior single-agent BRAF inhibitor.PATIENTS AND METHODS: In this two-centres, single-arm Phase 2 trial, we enrolled patients with systemic progressive disease during single-agent vemurafenib treatment. Participants received vemurafenib 960 mg twice daily or dose administered at time of disease progression with vemurafenib previous treatment and fotemustine 100 mg/m2 intravenously every three weeks. The primary endpoint was PFS.RESULTS: Thirty-one patients were enrolled in the study; 16 patients had brain metastases at baseline. Median PFS was 3.9 months and 19 patients (61.3{\%}) achieved disease control (1 CR, 4 PR, 14 SD). For patients achieving disease control, median duration of treatment was 6 months. Median OS was 5.8 months from enrolment and 15.4 months from start of previous vemurafenib. Five patients (16.1{\%}) had a G3-4 AE, the most common being thrombocytopenia, which occurred in 3 patients.This trial is registered with ClinicalTrials.gov number NCT01983124.CONCLUSION: The combination of vemurafenib plus fotemustine has clinical activity and an acceptable safety profile in BRAF-refractory patients.",
keywords = "Journal Article",
author = "Paola Queirolo and Francesco Spagnolo and Virginia Picasso and Laura Spano and Enrica Tanda and Valeria Fontana and Laura Giorello and Merlo, {Domenico Franco} and Ester Simeone and Grimaldi, {Antonio Maria} and Marcello Curvietto and {Del Vecchio}, Michele and Paolo Bruzzi and Ascierto, {Paolo Antonio}",
year = "2016",
month = "7",
day = "13",
doi = "10.18632/oncotarget.10589",
language = "English",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",

}

TY - JOUR

T1 - Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

AU - Queirolo, Paola

AU - Spagnolo, Francesco

AU - Picasso, Virginia

AU - Spano, Laura

AU - Tanda, Enrica

AU - Fontana, Valeria

AU - Giorello, Laura

AU - Merlo, Domenico Franco

AU - Simeone, Ester

AU - Grimaldi, Antonio Maria

AU - Curvietto, Marcello

AU - Del Vecchio, Michele

AU - Bruzzi, Paolo

AU - Ascierto, Paolo Antonio

PY - 2016/7/13

Y1 - 2016/7/13

N2 - BACKGROUND: BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression on prior single-agent BRAF inhibitor.PATIENTS AND METHODS: In this two-centres, single-arm Phase 2 trial, we enrolled patients with systemic progressive disease during single-agent vemurafenib treatment. Participants received vemurafenib 960 mg twice daily or dose administered at time of disease progression with vemurafenib previous treatment and fotemustine 100 mg/m2 intravenously every three weeks. The primary endpoint was PFS.RESULTS: Thirty-one patients were enrolled in the study; 16 patients had brain metastases at baseline. Median PFS was 3.9 months and 19 patients (61.3%) achieved disease control (1 CR, 4 PR, 14 SD). For patients achieving disease control, median duration of treatment was 6 months. Median OS was 5.8 months from enrolment and 15.4 months from start of previous vemurafenib. Five patients (16.1%) had a G3-4 AE, the most common being thrombocytopenia, which occurred in 3 patients.This trial is registered with ClinicalTrials.gov number NCT01983124.CONCLUSION: The combination of vemurafenib plus fotemustine has clinical activity and an acceptable safety profile in BRAF-refractory patients.

AB - BACKGROUND: BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospectively investigate the activity of prolonged treatment with vemurafenib and the addition of fotemustine in patients with systemic progression on prior single-agent BRAF inhibitor.PATIENTS AND METHODS: In this two-centres, single-arm Phase 2 trial, we enrolled patients with systemic progressive disease during single-agent vemurafenib treatment. Participants received vemurafenib 960 mg twice daily or dose administered at time of disease progression with vemurafenib previous treatment and fotemustine 100 mg/m2 intravenously every three weeks. The primary endpoint was PFS.RESULTS: Thirty-one patients were enrolled in the study; 16 patients had brain metastases at baseline. Median PFS was 3.9 months and 19 patients (61.3%) achieved disease control (1 CR, 4 PR, 14 SD). For patients achieving disease control, median duration of treatment was 6 months. Median OS was 5.8 months from enrolment and 15.4 months from start of previous vemurafenib. Five patients (16.1%) had a G3-4 AE, the most common being thrombocytopenia, which occurred in 3 patients.This trial is registered with ClinicalTrials.gov number NCT01983124.CONCLUSION: The combination of vemurafenib plus fotemustine has clinical activity and an acceptable safety profile in BRAF-refractory patients.

KW - Journal Article

U2 - 10.18632/oncotarget.10589

DO - 10.18632/oncotarget.10589

M3 - Article

C2 - 27418142

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

ER -